胃癌术后同步放化疗的临床观察

Clinical study of postoperative concurrent chemoradiotheraphy for gastric cancer

为了观察胃癌根治术后同步放化疗的疗效及毒副反应,将58例Ⅱ～Ⅳ期胃癌根治术后患者分为术后同步放化疗组(治疗组)和术后单纯化疗组(对照组),观察比较两组的1、2年生存率和治疗期间毒副反应。结果:治疗组和对照组1年生存率分别为92.8%和86.7%(P>0.05);2年生存率分别为85.7%和66.7%,差异有统计学意义,P<0.05;治疗组和对照组Ⅲ级以上血液学毒性分别为21.4%和16.6%(P>0.05),消化道反应25%和13.3%(P<0.05)。初步研究结果提示,胃癌术后同步放化疗可提高患者疗效,毒副反应可接受。

This study was to observe the efficacy and toxicity of postoperative concurrent chemoradiotherapy for gastric cancer.From February 2006 to December 2008,a prospective trial was performed in 58 patients with gastric cancer staged Ⅱ-Ⅳ（M0）after curative resection,and the patients were separated into concurrent chemoradiotherapy group（CRT）and chemotherapy alone group（CT）.Then,1,2-year survival rate and toxicity of the two groups were observed and compared.Results：the 1-year survival rate was 92.8% for the CRT group,while it was 86.7% for CT group（P〉0.05）.The 2-year survival rate was 85.7% vs 66.7%,the difference was statistically significant（P〈0.05）.Acute ≥grade 3 hematological toxicity was 21.4% vs 16.6%（P〉0.05）for the CRT and CT group each,and gastrointestinal toxicity was 25% vs 13.3%（P〈0.05）.In conclusion,the efficacy can be improved by the postoperative concurrent chemoradiotherapy for gastric cancer with acceptable toxicities.